Hospira Levophed injection recall: Foreign stopper during packaging
Hospira recalls Levophed norepinephrine injections with a foreign stopper observed during packaging. This GMP deviation may affect product safety.
Lower-risk recall
GMP Deviation; A foreign stopper was observed during packaging of a lot of product.
Contact the company
What happened, in plain English
Hospira is recalling Levoph: a medication injection used for medical purposes. The recall is due to a foreign stopper found during packaging, which could pose a safety risk if the injection is used. Read more at govinfonow.com/recall/41606-hospira-levophed-injection-recall-foreign-stopper-during-packaging.
Source Summary by GovInfoNow · govinfonow.com/recall/41606-hospira-levophed-injection-recall-foreign-stopper-during-packaging · Updated October 8, 2026 · FDA enforcement record: FDA #D-0898-2017
Cite this page
“Hospira Levophed injection recall: Foreign stopper during packaging.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41606-hospira-levophed-injection-recall-foreign-stopper-during-packaging. Based on FDA recall #D-0898-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0898-2017%22&limit=1).
Why it’s dangerous
During packaging, a foreign stopper was observed in some batches of Levophed injections. This could potentially cause injury if the injection is administered improperly.
Who’s affected
Healthcare professionals who use Levophed injections for medical treatment. Patients receiving this medication under medical supervision are also affected.
How to tell if you have this one
Check for the product name 'Levophed norepinephrine bitartrate injection, USP, 4 mg/4 mL (1 mg/mL), Rx only'. The NDC numbers 0409-3375-04 and 720503A (Canada) are also listed.
- Brand
Hospira- Category
Drug
What to do — step by step
Check Product Details
Verify the NDC numbers 0409-3375-04 and 720503A (Canada) to confirm if your product is affected.
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
FDA distribution: “Nationwide, Canada and Singapore” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA terminated this recall 23 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0898-2017 (May 18, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0898-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.